Live

Watch CBSN Live

Pfizer and Chantix: From Bad to Worse

Much as I suspected when I first wrote about Pfizer's attempts to minimize potentially serious neurological side effects of its smoking-cessation drug Chantix, the drugmaker's stonewalling tactics have simply made a bad situation worse. To wit:

It's all enough to make you wonder what the drug industry would look like if its leading companies took side-effect reports more seriously at an earlier stage, even at the risk of a temporary setback in sales. Not only would it be good corporate citizenship, it might go a long way toward restoring the industry's reputation and even enhancing the credibility of its marketing.

Don't hold your breath.

Further reading: Pfizer Spins, And Spins Some More on Chantix

View CBS News In